research technology and solutions
homeblood disease and transplantation immune disease detection technology programorgan transplantation
organ transplantation
the company has a comprehensive and comprehensive donor selection plan for patients with hla, dsa, c1q, kir, mica, sufu, and viruses.
hla
hematopoietic stem cell transplantation for donor selection
mica
organ transplant recipient selection
dsa c1q
avoid implant failure or failure, as donor selection and postoperative detection indicators, c1q further predicts implantation
kir
predicting the occurrence of transplanted organ rejection
microchimerism
sensitivity up to 0.001%, detecting the ratio of organ transplant donor cells in patients
cfdna
dynamic assessment of rejection after organ transplantation
virus
positive suggestive of viral infection, dynamic monitoring before and after transplantation
cell ratio
prediction of the risk of infection after organ transplantation- clinical service
- clinical cell molecular genetics test
- clinical blood and body fluid testing
- service overview
- knowledge center
- technology latform
- sequencing platform
- diagnostic platform
- computing and data platform
- sample storage platform
- research and technology solutions
- blood disease
- epilepsy medication guidance
- whole genome
- research cooperation
- technical team
- biological reagent
- class a medical device
- class iii medical devices
- contact us
- contact us
- cstb life
- careers
- links
shenzhen headquarters
address: building a17, life science industrial park, kwai chung street, dapeng new district, shenzhenshanghai headquarters
address: building 21, phase 4, shanghai international medical parknational hotline:400-808-7208
scan on us
©尊龙凯时 copyright shenzhen tissue bank precision medicine co., ltd. 尊龙凯时 copyright